Insulet (NASDAQ:PODD) Price Target Raised to $234.00 at Barclays

Insulet (NASDAQ:PODD) had its price objective increased by Barclays from $220.00 to $234.00 in a research report report published on Monday morning,Benzinga reports. The firm currently has an equal weight rating on the medical instruments supplier’s stock.

PODD has been the topic of a number of other reports. Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Morgan Stanley increased their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday. Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. BTIG Research raised their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Piper Sandler raised their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Down 0.8 %

NASDAQ PODD traded down $2.12 during trading hours on Monday, reaching $273.58. 31,272 shares of the company traded hands, compared to its average volume of 778,792. Insulet has a 12 month low of $156.00 and a 12 month high of $279.40. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The stock has a market capitalization of $19.18 billion, a PE ratio of 47.21, a PEG ratio of 5.00 and a beta of 1.22. The company has a 50 day moving average of $233.46 and a two-hundred day moving average of $205.26.

Hedge Funds Weigh In On Insulet

Several large investors have recently bought and sold shares of PODD. Janney Montgomery Scott LLC increased its stake in Insulet by 34.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 10,060 shares of the medical instruments supplier’s stock valued at $1,724,000 after buying an additional 2,573 shares during the period. Sei Investments Co. increased its stake in Insulet by 16.2% during the 1st quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock valued at $2,019,000 after buying an additional 1,639 shares during the period. Inspire Investing LLC increased its stake in Insulet by 26.0% during the 1st quarter. Inspire Investing LLC now owns 2,581 shares of the medical instruments supplier’s stock valued at $442,000 after buying an additional 533 shares during the period. Headlands Technologies LLC increased its stake in Insulet by 373.9% during the 1st quarter. Headlands Technologies LLC now owns 1,872 shares of the medical instruments supplier’s stock valued at $321,000 after buying an additional 1,477 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its stake in shares of Insulet by 3.8% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 78,435 shares of the medical instruments supplier’s stock worth $13,444,000 after purchasing an additional 2,847 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.